Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.

AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the …

2025年8月20日 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are …

2025年11月12日 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 inhibitor approved …

5 日前 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to reductions in the ...

2025年11月26日 · Learn about the FDA-approved treatment for tardive dyskinesia, specifically the VMAT2 inhibitors valbenazine (Ingrezza) and deutetrabenazine (Austedo).

2025年11月7日 · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of adults with tardive …

2025年10月22日 · Teva Pharmaceuticals announced new data from the ongoing, real-world IMPACT-TD Registry, which demonstrates that treatment with deutetrabenazine tablets or deutetrabenazine …

2024年5月29日 · AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …

2024年6月3日 · The FDA has approved Austedo XR in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with Huntington’s disease, according to the …